Corporate ActionJul 31, 2026, 10:14 AM
Moleculin Biotech Prices Public Offering of 12.3M Shares at $0.75
AI Summary
Moleculin Biotech, Inc. announced the pricing of a public offering consisting of 12,376,667 shares of common stock (or pre-funded warrants) and warrants to purchase up to 37,130,001 shares of common stock. The combined public offering price is $0.75 per share and associated warrant. The offering is expected to close around August 3, 2026, with net proceeds intended for advancing Annamycin through clinical development and for general working capital.
Key Highlights
- Public offering of 12,376,667 shares of common stock or pre-funded warrants.
- Warrants to purchase up to 37,130,001 shares of common stock included.
- Combined public offering price of $0.75 per share of common stock/warrant.
- Common Warrants immediately exercisable at $0.75 per share.
- Common Warrants will expire five years following the initial exercise date.
- Offering expected to close on or about August 3, 2026.
- Net proceeds to advance Annamycin clinical development and for working capital.
Price Impact
More from MBRX